Martine Zimmermann
Director/Board Member at INVENTIVA
Net worth: 167 034 $ as of 31/03/2024
Martine Zimmermann active positions
| Companies | Position | Start | End |
|---|---|---|---|
| INVENTIVA | Director/Board Member | 16/04/2021 | - |
| Independent Dir/Board Member | 16/04/2021 | - | |
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 26/09/2023 | - |
| Independent Dir/Board Member | 26/09/2023 | - | |
| Ipsen Biopharmaceuticals, Inc. | General Counsel | - | - |
Career history of Martine Zimmermann
Former positions of Martine Zimmermann
| Companies | Position | Start | End |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 01/06/2016 | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Director/Board Member | 01/03/2019 | 01/01/2021 |
Training of Martine Zimmermann
| University of Strasbourg | Doctorate Degree |
| Louis Pasteur University | Doctorate Degree |
Statistics
International
| United States | 5 |
| France | 4 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| General Counsel | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| INVENTIVA | Health Technology |
| Private companies | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. | |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Martine Zimmermann
- Experience